Clinical Trials

Inclusion Criteria:

• Age ≥ 65 years.
• Histologically confirmed newly diagnosed Grade IV malignant glioma.
• Planned radiation treatments at Mayo Clinic Arizona or Mayo Clinic Rochester.
• Willing to sign release of information for any radiation and/or follow-up records.
• Provide informed written consent.
• Patients with eGFR ≥ 60 mg/min/1.72m^2.
• Ability to complete questionnaire(s) by themselves or with assistance.
• ECOG performance status 0, 1, 2.

Exclusion Criteria:

• Patients diagnosed with Grades I-III glioma.
• Currently on Avastin at time of treatment.
• Unable to undergo MRI scans with contrast (e.g., cardiac pacemaker, defibrillator, kidney failure).
• Unable to undergo an 18F-DOPA-PET scan (e.g., Parkinson’s Disease, taking anti-dopaminergic, or dopamine agonist medication or less than 6 half-lives from discontinuance of dopamine agonists).
  • NOTE: Other potentially interfering drugs: amoxapine, amphetamine, benztropine, buproprion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, norephedrine, phentermine, phenylpropanolamine, selegiline, paroxetine, citalopram, and sertraline. If a patient is on any of these drugs, list which ones on the On-Study form.
• Pregnant women, nursing women, or men or women of childbearing potential who are unwilling to employ adequate contraception.
  • NOTE: All women enrolled in this study will be age 65 or over, and at the determination of the PI, will not be of childbearing potential.  If the radiology department requires a pregnancy test before administering the 18FDOPA injection, they may perform one per their standard of care.